Axogen (AXGN) Prices Upsized Offering of 4 Million Shares at $31, Raising Approximately $124 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy AXGN?
Source: NASDAQ.COM
- Stock Offering: Axogen has announced an upsized public offering of 4 million shares at $31 each, raising approximately $124 million, although this news has led to a nearly 5% decline in premarket trading.
- Use of Proceeds: The company intends to utilize the net proceeds for early repayment of its term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes, thereby optimizing its financial structure and enhancing liquidity.
- Underwriter Arrangement: Wells Fargo Securities and Mizuho are acting as lead book-running managers for the offering, ensuring a smooth financing process and boosting market confidence.
- Stock Price Fluctuation: AXGN has traded within a range of $9.22 to $34.71 over the past year, closing at $33.01 on Wednesday, up 3.58% from the previous day, indicating market interest in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXGN
Wall Street analysts forecast AXGN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.230
Low
39.00
Averages
39.80
High
40.00
Current: 37.230
Low
39.00
Averages
39.80
High
40.00
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aiming to enhance the company's leadership in cardiovascular treatment.
- Rich Industry Experience: Dale brings an outstanding record of commercial success in the medical device industry, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide valuable strategic guidance for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim is the first FDA-approved medical device utilizing neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market penetration of this technology, enhancing patient treatment outcomes.
- Global Market Compliance: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will aid CVRx in compliance and expansion in global markets.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
DAFNA Capital Management Reduces Axogen Holdings
- Share Reduction: DAFNA Capital Management cut its Axogen holdings by 265,456 shares in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategy focused on portfolio balance after a 70% stock price increase.
- Holding Status: At the end of the quarter, DAFNA retained 476,826 shares of Axogen, valued at $15.61 million, representing 3.63% of its 13F reportable assets, highlighting the company's significance in its investment portfolio.
- Market Performance: Axogen's stock price surged 71% over the past year to $30.78, significantly outperforming the S&P 500's approximate 15% increase during the same period, reflecting strong growth potential in the peripheral nerve repair market.
- Financial Overview: With a market capitalization of $1.6 billion and TTM revenue of $225.2 million, Axogen reported a net loss of $15.7 million; however, the company achieved approximately 20% revenue growth in its core surgical markets, indicating ongoing double-digit expansion potential.
See More
Axogen Reports Q4 2025 Earnings with Strong Growth and FDA Milestone
- Financial Performance Growth: Axogen reported Q4 2025 revenue of $59.9 million, reflecting a 21.3% year-over-year increase, with full-year revenue reaching $225.2 million, demonstrating strong double-digit growth across all target markets and laying a solid foundation for sustainable future growth.
- FDA Approval Milestone: The company achieved a historic milestone with the FDA approval of the biologics license application (BLA) for Avance, granting 12 years of market exclusivity and establishing its standard position in nerve repair, which is expected to drive future market expansion.
- Capital Structure Optimization: Axogen completed an upsized public offering raising $133.3 million, using $69.7 million to retire its term loan, significantly improving its capital structure and enhancing financial flexibility to support future investments.
- Market Expansion Plans: The company plans to further expand its sales team in 2026, particularly in the Breast and Extremities markets, with expectations to grow the Breast team to 30 sales representatives and the Extremities team to 130, indicating a proactive approach to capturing market opportunities.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aiming to enhance the company's leadership in cardiovascular treatment.
- Rich Industry Experience: Dale brings an outstanding record of commercial success in the medical device industry, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide valuable strategic guidance for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim is the first FDA-approved medical device utilizing neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market penetration of this technology, enhancing patient treatment outcomes.
- Global Market Compliance: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will aid CVRx in compliance and expansion in global markets.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
DAFNA Capital Management Reduces Axogen Holdings
- Share Reduction: DAFNA Capital Management cut its Axogen holdings by 265,456 shares in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategy focused on portfolio balance after a 70% stock price increase.
- Holding Status: At the end of the quarter, DAFNA retained 476,826 shares of Axogen, valued at $15.61 million, representing 3.63% of its 13F reportable assets, highlighting the company's significance in its investment portfolio.
- Market Performance: Axogen's stock price surged 71% over the past year to $30.78, significantly outperforming the S&P 500's approximate 15% increase during the same period, reflecting strong growth potential in the peripheral nerve repair market.
- Financial Overview: With a market capitalization of $1.6 billion and TTM revenue of $225.2 million, Axogen reported a net loss of $15.7 million; however, the company achieved approximately 20% revenue growth in its core surgical markets, indicating ongoing double-digit expansion potential.
See More
Axogen Reports Q4 2025 Earnings with Strong Growth and FDA Milestone
- Financial Performance Growth: Axogen reported Q4 2025 revenue of $59.9 million, reflecting a 21.3% year-over-year increase, with full-year revenue reaching $225.2 million, demonstrating strong double-digit growth across all target markets and laying a solid foundation for sustainable future growth.
- FDA Approval Milestone: The company achieved a historic milestone with the FDA approval of the biologics license application (BLA) for Avance, granting 12 years of market exclusivity and establishing its standard position in nerve repair, which is expected to drive future market expansion.
- Capital Structure Optimization: Axogen completed an upsized public offering raising $133.3 million, using $69.7 million to retire its term loan, significantly improving its capital structure and enhancing financial flexibility to support future investments.
- Market Expansion Plans: The company plans to further expand its sales team in 2026, particularly in the Breast and Extremities markets, with expectations to grow the Breast team to 30 sales representatives and the Extremities team to 130, indicating a proactive approach to capturing market opportunities.
See More
